Levothyroxine | L-Thyroxine | CAS#55-03-8 | Thyroid Gland Hormone

MedKoo Cat#: 531035 | Name: Levothyroxine sodium

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levothyroxine, also known as L-Thyroxine, is hormone derived from the thyroid gland. Levothyroxine therapy is used in case of deficiency of the thyroid hormones in the human organism. Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism.

Chemical Structure

Levothyroxine sodium

CAS#55-03-8 (sodium)

Theoretical Analysis

MedKoo Cat#: 531035

Name: Levothyroxine sodium

CAS#: 55-03-8 (sodium)

Chemical Formula: C15H10I4NNaO4

Exact Mass: 776.6867

Molecular Weight: 798.67

Elemental Analysis: C, 22.55; H, 1.26; I, 63.54; N, 1.75; Na, 2.88; O, 8.01

Price and Availability

Size	Price	Availability
1g	USD 150.00	2 Weeks
2g	USD 250.00	2 Weeks
5g	USD 450.00	2 Weeks
10g	USD 750.00	2 Weeks
25g	USD 1,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

51-48-9 (free) 55-03-8 (sodium) 6106-07-6 (sodium pentahydrate) 25416-65-3 (sodium hydrate)

Synonym

Levothyroxine sodium, Levothyroxine,Levothyroxine sodium, Levothyroxine sodium pentahydrate, L-Thyroxin, L Thyroxin, T4, Thyroxine

IUPAC/Chemical Name

(S)-2-amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)propanoic acid sodium salt

InChi Key

YDTFRJLNMPSCFM-YDALLXLXSA-M

InChi Code

InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m0./s1

SMILES Code

O=C([O-])[C@@H](N)CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1.[Na+]

Appearance

Off-white to yellow solid powder.

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism.

In vitro activity:

TBD

In vivo activity:

Tracheal responsiveness to methacholine and MDA concentration (p < 0.05) were decreased in AD (Alzheimer’s disease) rats treated with T4 compared to the AD group. Reference: Respir Physiol Neurobiol. 2020 Jun;277:103437. https://pubmed.ncbi.nlm.nih.gov/32259689/

	Solvent	mg/mL	mM
Solubility
	1M NaOH	5.0	6.44
	DMF	0.1	0.18
	DMSO	117.5	151.25
	DMSO:PBS (pH 7.2) (1:5)	0.5	0.64

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 798.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Bavarsad K, Saadat S, Mohammadian Roshan N, Hadjzadeh MA, Boskabady MH. Effects of levothyroxine on lung inflammation, oxidative stress and pathology in a rat model of Alzheimer's disease. Respir Physiol Neurobiol. 2020 Jun;277:103437. doi: 10.1016/j.resp.2020.103437. Epub 2020 Apr 5. PMID: 32259689. 2. Bavarsad K, Hadjzadeh MA, Hosseini M, Pakdel R, Beheshti F, Bafadam S, Ashaari Z. Effects of levothyroxine on learning and memory deficits in a rat model of Alzheimer's disease: the role of BDNF and oxidative stress. Drug Chem Toxicol. 2020 Jan;43(1):57-63. doi: 10.1080/01480545.2018.1481085. Epub 2018 Jun 21. PMID: 29927658.

In vitro protocol:

TBD

In vivo protocol:

1: Geer M, Potter DM, Ulrich H. Alternative schedules of levothyroxine administration. Am J Health Syst Pharm. 2015 Mar 1;72(5):373-7. doi: 10.2146/ajhp140250. Review. PubMed PMID: 25694412. 2: Ianiro G, Mangiola F, Di Rienzo TA, Bibbò S, Franceschi F, Greco AV, Gasbarrini A. Levothyroxine absorption in health and disease, and new therapeutic perspectives. Eur Rev Med Pharmacol Sci. 2014;18(4):451-6. Review. PubMed PMID: 24610609. 3: Escobar-Morreale HF, Botella-Carretero JI, Morreale de Escobar G. Treatment of hypothyroidism with levothyroxine or a combination of levothyroxine plus L-triiodothyronine. Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):57-75. doi: 10.1016/j.beem.2014.10.004. Epub 2014 Oct 25. Review. PubMed PMID: 25617173. 4: Wood MD, Delate T, Clark M, Clark N, Horn JR, Witt DM. An evaluation of the potential drug interaction between warfarin and levothyroxine. J Thromb Haemost. 2014 Aug;12(8):1313-9. doi: 10.1111/jth.12626. Epub 2014 Jun 25. PubMed PMID: 24913218. 5: Trifirò G, Parrino F, Sultana J, Giorgianni F, Ferrajolo C, Bianchini E, Medea G, Benvenga S, Cricelli I, Cricelli C, Lapi F. Drug interactions with levothyroxine therapy in patients with hypothyroidism: observational study in general practice. Clin Drug Investig. 2015 Mar;35(3):187-95. doi: 10.1007/s40261-015-0271-0. PubMed PMID: 25643810. 6: Seng Yue C, Benvenga S, Scarsi C, Loprete L, Ducharme MP. When Bioequivalence in Healthy Volunteers May not Translate to Bioequivalence in Patients: Differential Effects of Increased Gastric pH on the Pharmacokinetics of Levothyroxine Capsules and Tablets. J Pharm Pharm Sci. 2015;18(5):844-55. PubMed PMID: 26670370. 7: Andersen MN, Olsen AM, Madsen JC, Faber J, Torp-Pedersen C, Gislason GH, Selmer C. Levothyroxine Substitution in Patients with Subclinical Hypothyroidism and the Risk of Myocardial Infarction and Mortality. PLoS One. 2015 Jun 12;10(6):e0129793. doi: 10.1371/journal.pone.0129793. eCollection 2015. PubMed PMID: 26069971; PubMed Central PMCID: PMC4466400. 8: Robertson HM, Narayanaswamy AK, Pereira O, Copland SA, Herriot R, McKinlay AW, Bevan JS, Abraham P. Factors contributing to high levothyroxine doses in primary hypothyroidism: an interventional audit of a large community database. Thyroid. 2014 Dec;24(12):1765-71. doi: 10.1089/thy.2013.0661. PubMed PMID: 25203248. 9: Formenti AM, Daffini L, Pirola I, Gandossi E, Cristiano A, Cappelli C. Liquid levothyroxine and its potential use. Hormones (Athens). 2015 Apr-Jun;14(2):183-9. doi: 10.14310/horm.2002.1579. Review. PubMed PMID: 26158650. 10: Hamad ML, Engen W, Morris KR. Impact of hydration state and molecular oxygen on the chemical stability of levothyroxine sodium. Pharm Dev Technol. 2015 May;20(3):314-9. doi: 10.3109/10837450.2013.862635. Epub 2013 Dec 3. PubMed PMID: 24295156. 11: Stamm TJ, Lewitzka U, Sauer C, Pilhatsch M, Smolka MN, Koeberle U, Adli M, Ricken R, Scherk H, Frye MA, Juckel G, Assion HJ, Gitlin M, Whybrow PC, Bauer M. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014 Feb;75(2):162-8. doi: 10.4088/JCP.12m08305. PubMed PMID: 24345793. 12: Dörr HG, Bettendorf M, Binder G, Karges B, Kneppo C, Schmidt H, Voss E, Wabitsch M, Dötsch J. Levothyroxine Treatment of Euthyroid Children with Autoimmune Hashimoto Thyroiditis: Results of a Multicenter, Randomized, Controlled Trial. Horm Res Paediatr. 2015;84(4):266-74. doi: 10.1159/000437140. Epub 2015 Aug 7. PubMed PMID: 26279111. 13: Catalina PF, Carpio D. [Levothyroxine malabsortion]. Med Clin (Barc). 2015 Jul 6;145(1):46. doi: 10.1016/j.medcli.2014.09.007. Epub 2014 Nov 13. Spanish. PubMed PMID: 25458511. 14: Foeller ME, Silver RM. Combination Levothyroxine + Liothyronine Treatment in Pregnancy. Obstet Gynecol Surv. 2015 Sep;70(9):584-6. doi: 10.1097/OGX.0000000000000217. Review. PubMed PMID: 26403562. 15: Perez CL, Araki FS, Graf H, de Carvalho GA. Serum thyrotropin levels following levothyroxine administration at breakfast. Thyroid. 2013 Jul;23(7):779-84. doi: 10.1089/thy.2012.0435. Epub 2013 Jun 21. PubMed PMID: 23363386. 16: Pai G, Jain V. Massive levothyroxine ingestion. Indian Pediatr. 2014 Oct;51(10):840-1. PubMed PMID: 25362025. 17: Orgiazzi J, Wémeau JL. [Levothyroxine and generics: current reflections]. Rev Prat. 2014 Mar;64(3):304-6. French. PubMed PMID: 24851355. 18: Livingston M, Birch K, Guy M, Kane J, Heald AH. No role for tri-iodothyronine (T3) testing in the assessment of levothyroxine (T4) over-replacement in hypothyroid patients. Br J Biomed Sci. 2015;72(4):160-3. PubMed PMID: 26738396. 19: Iovino M, Iovine N, Petrosino A, Giagulli VA, Licchelli B, Guastamacchia E, Triggiani V. Sevelamer carbonate markedly reduces levothyroxine absorption. Endocr Metab Immune Disord Drug Targets. 2014;14(3):206-9. PubMed PMID: 25183496. 20: McAninch EA, Bianco AC. New insights into the variable effectiveness of levothyroxine monotherapy for hypothyroidism. Lancet Diabetes Endocrinol. 2015 Oct;3(10):756-8. doi: 10.1016/S2213-8587(15)00325-3. Epub 2015 Sep 8. PubMed PMID: 26362364; PubMed Central PMCID: PMC5006060